Article Information
History
- July 28, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Gayatri Amirthalingam*,1,
- Jamie Lopez Bernal1,
- Nick J Andrews2,
- Heather Whitaker2,
- Charlotte Gower1,
- Julia Stowe1,
- Elise Tessier1,
- Vani Subbarao1,
- Georgina Ireland1,
- Frances Baawuah1,3,
- Ezra Linley4,
- Lenesha Warrener5,
- Michelle O’Brien3,
- Corinne Whillock1,
- Paul Moss6,
- Shamez N Ladhani1,7,
- Kevin E Brown1 and
- Mary E Ramsay1
- 1Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom
- 2Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom
- 3Brondesbury Medical Centre, Kilburn, London, United Kingdom
- 4Sero-Epidemiolgy Unit, National Infection Service, Public Health England, Manchester, United Kingdom
- 5Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom
- 6Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom
- 7Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom
- ↵*Correspondence: Gayatri Amirthalingam (gayatri.amirthalingam{at}phe.gov.uk)
Posted July 28, 2021.
Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England
